Hyper-Progressive Cancers and the Covid Vax By Brian Simpson
This is an issue that we in Australia should be concerned with: the rise of hyper-progressive, and aggressive cancers. In Australia there has been a highly statistically significant rise in reported cancer deaths of 7 percent, which precisely corresponds to the Covid vax rollout time frame. Normally, cancer tends to be relatively slow growing (with some notable exceptional aggressive cancers), so the rise of these aggressive cancers is a deep concern. But health authorities and the federal government seemingly are not interested in pursuing a Covid vax cause to this. The really big question is if the cancers are vax caused, will there continue to be an increase in these cancers in the future?
While the issues are technical, Ivor Chudov has given an excellent summary of the medical details that exist, where repeat injections of mRNA Covid vaccines, trigger the release of a rare group of antibodies called IgG4. These antibodies are usually released by the body to deal with persistent irritants such as parasitic worms. But having these IgG4 antibodies released increases the risks of cancer. The extract below goes into detail about how this operates for those with a more technical mind. But the problem is that, as Dr Peter McCullough and others have noted, IgG4 is also stimulated by the Covid mRNA vax, and especially by repeated injections. The billions of spike proteins that circulate in the body, provide more than enough persistent irritation to set off the IgG4 production in high speed. This would explain the rise in these aggressive cancers which sometimes kill patients only months after initial diagnosis.
It is a national disgrace that the parliament of Australia is so in hock to Big Pharma, that there is no formal investigation of the country’s excess mortality.
“A while ago, I explored a unique, rare class of antibodies called IgG4, caused by repeat injections of mRNA Covid vaccines.
These IgG4 antibodies are usually created in response to persistent irritants such as worms. Unfortunately, repeat injections of mRNA Covid vaccine are perceived by our immune systems as a ‘persistent irritant’ and cause the IgG4 antibody switch.
The ‘persistent irritation’ effect possibly occurs not only because of repeat injections but also due to mRNA gene expression never stopping in half of the vaccinated people.
Are these IgG4 antibodies harmless? Do they have any effects outside of our immune reactions to COVID-19? Is there something to worry about?
Unfortunately, a 2020 study published in the British Medical Journal’s Journal for Immunotherapy of Cancer suggests that having more IgG4 antibodies — of any kind – enhances cancer progression. The study by Wang et al. was done two years before the discovery of mRNA vaccine-related class switch to IgG4 antibodies.
The study authors found cancer-enhancing effects of any IgG4 antibodies in people and laboratory mice.
RESULTS: In a cohort of patients with esophageal cancer we found that IgG4-containing B lymphocytes and IgG4 concentration were significantly increased in cancer tissue and IgG4 concentrations increased in serum of patients with cancer. Both were positively related to increased cancer malignancy and poor prognoses, that is, more IgG4 appeared to associate with more aggressive cancer growth. We further found that IgG4, regardless of its antigen specificity, inhibited the classic immune reactions of antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis and complement-dependent cytotoxicity against cancer cells in vitro, and these effects were obtained through its Fc fragment reacting to the Fc fragments of cancer-specific IgG1 that has been bound to cancer antigens. … We found that local application of IgG4 significantly accelerated growth of inoculated breast and colorectal cancers and carcinogen-induced skin papilloma. We also tested the antibody drug for cancer immunotherapy nivolumab, which was IgG4 in nature with a stabilising S228P mutation, and found that it significantly promoted cancer growth in mice. This may provide an explanation to the newly appeared hyperprogressive disease sometimes associated with cancer immunotherapy.
The scientists provide an excellent explanation of the IgG4 antibody subclass:
IgG4 is a unique antibody that has the lowest concentration among IgG subtypes in healthy individuals, and its function has not been well understood. IgG4 was regarded as a ‘blocking antibody’ because of its reduced ability to trigger effector immune reactions. Therefore whatever molecules IgG4 reacts to, the subsequent immune reaction was subdued.
The study details Wang et al.’s multidimensional investigation of IgG4 in a wide array of patients with cancer and tissues with both in vitro and in vivo experiments. Again, this research was done in 2020, well before the effects of Covid vaccines on IgG4 could be seen.
After collecting blood and tissue samples from 82 patients, scientists found that greater levels of IgG4 were associated with higher grade (cancer grade is the tumor’s degree of malignancy) and poor prognosis.
Do IgG4 antibodies cause worse cancer outcomes, or do worse cancers create more IgG4? What is the horse and what is the cart here?
The rest of the scientific study tries to answer this question, and scientists conclude that IgG4 drives malignancy and aggressiveness of the real-life cancers they observed.
They found that even non-cancer-specific IgG4 inhibited immune reactions to cancer cells. Since human experiments of this kind would be unethical, authors instead experimented with mouse models.
The authors describe hyperprogressive disease that occurs due to certain monoclonal IgG4-based antibody nivolumab, despite previous hopes of its potential usefulness.
Recent awareness of hyperprogressive disease (HPD) associated with anti-PD-1 and anti-PD-L1 monoclonal antibody treatment for cancer has caught widespread attention, but no consensual explanation for this phenomenon has arrived. HPD appeared to be a common complication for immunotherapy with nivolumab in many cancer types, including head and neck squamous cell carcinoma, non-small cell lung cancer, gastric cancer and so on. Our findings suggest that these IgG4 antibody drugs might have undesired side effects of inhibiting local immune responses and indirectly promote cancer growth. When the specific target molecule is present in cancer, these IgG4 antibody drugs might be effective. However, when the targets are absent or scanty, the IgG4’s immune inhibitory effect might prevail and accelerate cancer growth. This possible detrimental effect of IgG4 might contribute to HPD in patients treated with PD-1 targeting drugs with IgG4 structure.
What is ‘hyperprogressive disease’? It is the same thing as ‘turbo-cancer’, of course, but it is a more fitting scientific term.
The authors conclude:
Conclusion There appears to be a previously unrecognised immune evasion mechanism with IgG4 playing an essential role in cancer microenvironment with implications in cancer diagnosis and immunotherapy.
Cancer Deaths Increase in Australia
Unfortunately, relatively few recent cancer statistics are officially available. An internet researcher named the Ethical Skeptic found some recent alarming numbers. I do not want to highlight any of his specific findings because I have not yet been able to verify them personally, but my readers may take a critical look of their own.
However, what is available is about a 7% increase in cancer deaths reported in Australia, a highly vaccinated country. Since cancers typically take years to develop and grow, such an increase is concerning, given that only two years passed since Australians received their ‘safe and effective’ vaccines.
My work never takes cheap shots at vaccinated people and does not make unfounded, dire predictions not supported by evidence. I would rather forgo additional clicks and subscribers than misinform my readers. Let me summarise my reasons for hope that these biological findings will hopefully leave some people unscathed.
- We are only beginning to understand the effects of IgG4 antibodies on cancer
- Only about half of vaccinated people produce IgG4 antibodies in quantity
- Even though experiments showed increases in IgG4 over time, these antibodies may wane over the long run
- No evidence to date suggests that IgG4 antibodies causecancer – the evidence only points to them enhancing and speeding up existing cancers
What the evidence shows is that some cancers, possibly treatable before mRNA injections, may become aggressive and difficult to treat, a condition that the BMJ study authors call “hyperprogressive disease”.
I hope and pray that the number of people affected by ‘hyperprogressive disease’ will be low – and I hope that my readers will agree with this statement.”
Comments